MedCity News March 17, 2025
AstraZeneca’s EsoBiotec acquisition is the latest in a series of deals struck by the pharma giant to secure a place in the next wave of cell therapies for cancer and immune-mediated diseases. EsoBiotec’s allogeneic cell therapies are made by the in vivo reprogramming of a patient’s immune cells.
AstraZeneca already has cell therapies in its pipeline, and it is now expanding its scope further with a deal to acquire EsoBiotec, a company in early clinical development with therapies made by engineering immune cells inside a patient’s body.
Under acquisition terms announced Monday, AstraZeneca will pay $425 million up front for all outstanding equity of privately held EsoBiotec. The Cambridge, England-based pharmaceutical giant could pay out up to $575 million more...
Today's Sponsors
Today's Sponsor